Warner Huh, MD
Gynecologic Oncology · Birmingham, ALNPI 1043257173
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,575 of the $58,529 with a category attached, or 62.5%. 11 manufacturers reported payments, led by Chugai Pharmaceutical Co., Ltd. at 35.2% of the total. Reporting peaked in 2019 at $21,083 and has fallen 91.3% since, to $1,830 in 2023. Among gynecologic oncology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $1672.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chugai Pharmaceutical Co., Ltd.$21K
- AstraZeneca$17K
- Roche Diagnostics Corporation$8K
- Seagen Inc.$8K
- Dysis Medical, Inc.$3K
- Merck$2K
- plus $526 from 5 others
Across 3 payments — averaging $7003.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$21K
What the payments were for
- Consulting fees$36,57562%
- Speaking & faculty fees$1,9803%
- Travel & lodging$19,72734%
- Food & beverage$2230%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | 3 | $20,606 |
| AstraZeneca | 5 | $16,783 |
| Roche Diagnostics Corporation | 10 | $8,173 |
| Seagen Inc. | 8 | $8,073 |
| Dysis Medical, Inc. | 3 | $2,538 |
| Merck | 1 | $1,830 |
| Intuitive Surgical | 1 | $475 |
| Eisai Inc. | 1 | $22 |
| Secura Bio, Inc. | 1 | $14 |
| GSK | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Avastin$20,606
- LYNPARZA$16,783
- CINtec PLUS Cytology$4,334
- Ultra 2.0$2,538
- GARDASIL 9$1,830
- Da Vinci Surgical System$475
How this compares
$58,529 in reported general payments places this provider in the 90th percentile of 27 gynecologic oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 19 | $146 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Birmingham
- Charles LeathBirmingham$148K
- Rebecca ArendBirmingham$70K
- David DooBirmingham$9K
- Michael ToboniBirmingham$8K
- Margaret LiangBirmingham$3K
- Wesley BurkettBirmingham$3K
- Monjri ShahBirmingham$2K
- Kaitlyn DinkinsBirmingham$2K
- Christopher MayerBirmingham$1K
- Teresa BoitanoBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.